HOME >> BIOLOGY >> NEWS
Columbia researcher identifies cellular defect that may contribute to autism

NEW YORK, NY, January 27 The causes of autism have long remained a mystery, but new research from Columbia University Medical Center has identified, for the first time, how a cellular defect may be involved in the often crippling neurological disorder.

The research, which is published in today's issue of Science, examines how a defect in neuroligin genes may contribute to autism. Neuroligins are components of synapses, which connect individual neurons in the brain. The researchers found that the loss of neuroligins perturbs the formation of neuronal connections and results in an imbalance of neuronal function. This imbalance provides an explanation for the neurodevelopmental defects in autistic children.

"Understanding the cellular defects that may underlie autism-spectrum disorders represents an important step towards the goal of providing therapies," said Peter Scheiffele, Ph.D., assistant professor of physiology and cellular biophysics at Columbia University Medical Center, and principal investigator on the study.

A defect in the neuroligin genes had previously been observed in autistic patients, but its functional significance was not yet understood. Scheiffele's study showed that in rat neurons without any neuroligin, connections between neurons are altered in a way that is strikingly similar to those found in autistic children.

Each neuron in the brain receives many different inputs some are excitatory and signal the neuron to fire, and some are inhibitory and signal the neuron to stop firing. Scheiffele's research team found that neuroligin genes are responsible for regulating the balance between excitatory and inhibitory synaptic function. A defect in neuroligin leads to a selective loss in inhibitory function and thereby impairs the fine-tuning of neuronal connectivity, a neurological problem that is understood to play a role in autism.

"There is much we still don't know about how neurons con
'"/>

Contact: Craig LeMoult
cel2113@columbia.edu
212-305-0820
Columbia University Medical Center
27-Jan-2005


Page: 1 2

Related biology news :

1. Columbia University Medical Center awarded $3 million to drive Alzheimers genetics research
2. Columbia scientists determine 3-dimensional structure of cells fuel gauge
3. Columbia University licenses next-generation DNA sequencing technology
4. New bird discovered on unexplored Columbian mountain
5. Columbia University Medical Center receives major new NIH Clinical Science investment funds
6. Columbia University awards 2006 Horwitz Prize to biologist who explained gene transcription
7. Columbia University receives $16.9 million NIEHS award to study arsenic in ground water
8. Contaminants linked to sturgeon decline in Columbia river
9. Columbia University Medical Center researchers discover potential mechanism for tumor growth
10. UF, Columbia scientists closer to new cancer detection method
11. Columbia University awards 2005 Horwitz Prize to Israeli structural biologist

Post Your Comments:
(Date:2/10/2015)... 2015  Alere Inc. (NYSE: ALR), a global ... for the quarter ended December 31, 2014. ... of Alere said, "We made substantial progress in ... global leader in rapid diagnostics and delivering against ... divestiture in early January enabled us to substantially ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... been made aware of a fraudulent press release disseminated ... purporting to be from Immunovaccine. This press release states ... Gilead Science, Inc. The press release did not ... the information contained within the press release. Please ...
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
(Date:2/27/2015)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... that it will be presenting at CALBIO 2015 at ... at 3pm PST. Patrick Lucy, chief business officer of ... state of the biosimilar industry landscape entitled The ... more information on CALBIO 2015 and The Evolving ...
(Date:2/27/2015)... PureTech , a science and technology R&D company focused  ... in the healthcare sector, announced today the appointment of ... the Board of Directors of Sanofi, to its Board ... pleasure to know Chris for many years and I ... more closely now," said Dr. Robert Langer , ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
Cached News: